Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 송태진 | * |
dc.contributor.author | 박진 | * |
dc.contributor.author | 김지은 | * |
dc.date.accessioned | 2023-01-04T16:31:14Z | - |
dc.date.available | 2023-01-04T16:31:14Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 0148-639X | * |
dc.identifier.other | OAK-32571 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/263013 | - |
dc.description.abstract | Introduction/Aims: There are limited studies on the association of COVID-19 vaccination with neuralgic amyotrophy (NA). Therefore, we evaluated the association between COVID-19 vaccination and the occurrence of NA. Methods: We explored unexpected safety signals for NA related to COVID-19 vaccination through disproportionality analysis using VigiBase, the World Health Organization's pharmacovigilance database. Results: On October 15, 2021, 335 cases of NA were identified in the database. The median time to onset of NA after vaccination was around 2 weeks. A significant signal of disproportionality of NA was observed for the ChAdOx1 nCoV-19 vaccine (AstraZeneca) (information component [IC]025 = 0.33, reporting odds ratio [ROR]025 = 1.30) and two mRNA-based COVID-19 vaccines (BNT162b2 [Pfizer and BioNTech] and mRNA-1273 [Moderna]) (IC025 = 1.74, ROR025 = 3.82) compared with the entire database. However, when compared with influenza vaccines, we did not detect any signal of disproportionality of NA for both the ChAdOx1 nCoV-19 vaccine (IC025 = −2.71, ROR025 = 0.05) and mRNA-based COVID-19 vaccines (IC025 = −1.38, ROR025 = 0.13). Discussion: A weak association was observed between NA and COVID-19 vaccines. However, the risk did not surpass that of influenza vaccines. © 2022 Wiley Periodicals LLC. | * |
dc.language | English | * |
dc.publisher | John Wiley and Sons Inc | * |
dc.subject | COVID-19 | * |
dc.subject | neuralgic amyotrophy | * |
dc.subject | Parsonage-Turner syndrome | * |
dc.subject | SARS-CoV-2 | * |
dc.subject | vaccination | * |
dc.title | Associations of neuralgic amyotrophy with COVID-19 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database | * |
dc.type | Article | * |
dc.relation.issue | 6 | * |
dc.relation.volume | 66 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 766 | * |
dc.relation.lastpage | 770 | * |
dc.relation.journaltitle | Muscle and Nerve | * |
dc.identifier.doi | 10.1002/mus.27734 | * |
dc.identifier.wosid | WOS:000871932700001 | * |
dc.identifier.scopusid | 2-s2.0-85140433439 | * |
dc.author.google | Kim J.-E. | * |
dc.author.google | Park J. | * |
dc.author.google | Min Y.G. | * |
dc.author.google | Hong Y.-H. | * |
dc.author.google | Song T.-J. | * |
dc.contributor.scopusid | 송태진(55507164200) | * |
dc.contributor.scopusid | 박진(57209628952) | * |
dc.contributor.scopusid | 김지은(36663634500) | * |
dc.date.modifydate | 20240318140943 | * |